1
Eugene R Cooper: Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one. The Procter & Gamble Company, George W Allen, Steven J Goldstein, Jack D Schaeffer, December 10, 1985: US04557934 (164 worldwide citation)

Improved topical pharmaceutical compositions containing a pharmaceutically-active agent and the penetration enhancing agent 1-dodecylazacycloheptan-2-one are disclosed. This agent is used at selected levels in combination with certain C.sub.3 -C.sub.4 diols or a 1-substituted azacycloalkyl-2-one. Th ...


2
Eugene R Cooper: Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone. The Procter & Gamble Company, George W Allen, Steven J Goldstein, Richard C Witte, August 27, 1985: US04537776 (133 worldwide citation)

Topical pharmaceutical compositions comprising a pharmaceutically-active agent and a novel, penetration-enhancing vehicle or carrier are disclosed. The vehicle or carrier comprises a binary combination of N-(2-Hydroxyethyl) pyrrolidone and a "cell-envelope disordering compound". The compositions pro ...


3
Eugene R Cooper, Maurice E Loomans, Richard R Wickett: Penetrating topical pharmaceutical compositions. The Procter & Gamble Company, Milton B Graff IV, George W Allen, Steven J Goldstein, September 4, 1990: US04954487 (128 worldwide citation)

A large group of lipophilic, pharmacologically active compounds can be effectively delivered across intact skin by applying them topically in a binary, penetration-enhancing vehicle containing (1) a C.sub.3 -C.sub.4 diol, diol ester, or diol ether and (2) a cell envelope-disordering compound. This v ...


4
H William Bosch, Eugene R Cooper, Simon L McGurk: Bioadhesive nanoparticulate compositions having cationic surface stabilizers. Elan Pharma International, Foley & Lardner, August 6, 2002: US06428814 (117 worldwide citation)

Bioadhesive nanoparticulate compositions, comprising active agent particles and one or more cationic surface stabilizers, are described. The cationic surface stabilizers prevent aggregation of the nanoparticles and increase bioadhesion of the nanoparticles to biological substrates, such as an insect ...


5
Eugene R Cooper, Maurice E Loomans, Mahdi B Fawzi: Penetrating topical pharmaceutical compositions containing corticosteroids. The Procter & Gamble Company, George W Allen, Jack D Schaeffer, Steven J Goldstein, November 12, 1985: US04552872 (99 worldwide citation)

Topical pharmaceutical compositions containing a corticosteroid component and a penetration-enhancing vehicle are disclosed. The vehicle comprises a binary combination of a C.sub.3 -C.sub.4 diol and a "cell-envelope disordering compound". The vehicle provides marked transepidermal and percutaneous d ...


6
Gary G Liversidge, Eugene R Cooper, J Michael Shaw, Gregory L McIntire: X-ray contrast compositions useful in medical imaging. Sterling Winthrop, William J Davis, June 7, 1994: US05318767 (97 worldwide citation)

An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, and a pharmace ...


7
Sui Ming Wong, Eugene R Cooper, Shugian Xu: Polyalkylene block copolymers as surface modifiers for nanoparticles. NanoSystems L L C, Rudman & Balogh, October 15, 1996: US05565188 (96 worldwide citation)

There is disclosed a composition containing nanoparticles having a surface modifier wherein the surface modifier is a block copolymer containing one or more polyoxyethylene blocks and one or more polyoxy(higher alkylene) blocks wherein at least some of the blocks are linked together by a linking gro ...


8
Stephen B Ruddy, W Mark Eickhoff, Gary Liversidge, Eugene R Cooper: Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays. Nanosystems L L C, December 17, 1996: US05585108 (80 worldwide citation)

Nanoparticulate crystalline therapeutic substances formulated with stabilizers and pharmaceutically acceptable clays to enhance contact between the crystalline therapeutic substances and the gastrointestinal tract and to provide extended therapeutic effect.


9
H William Bosch, Kevin D Ostrander, Eugene R Cooper: Liquid droplet aerosols of nanoparticulate drugs. Elan Pharma International, Foley & Lardner, November 2, 2004: US06811767 (66 worldwide citation)

There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of t ...


10
Tai Lee Ke, Eugene R Cooper, Douglas F Hager, Jamieson C Keister: Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs. Alcon Laboratories, James A Arno, Sally S Yeager, June 22, 1993: US05221696 (66 worldwide citation)

The use of monoacyl phosphoglycerides to enhance the penetration of topically applied ophthalmic drugs through the corneal epithelium is described.